Sylwia Mazurek

Dr. Sylwia Mazurek

Department of Cancer Immunology, Chair of Medical Biotechnology, Poznan University of Medical Sciences, Poznan 61-701, Poland.
+1

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
OKOliwia Koteluk
Oliwia Koteluk
AWAdrian Wartecki
Adrian Wartecki
SMSylwia Mazurek
Sylwia Mazurek
IKIga Kołodziejczak
Iga Kołodziejczak
Andrzej MackiewiczAndrzej Mackiewicz
Andrzej Mackiewicz
With an increased number of medical data generated every day, there is a strong need for reliable, automated evaluation tools. With high hopes and expectations, machine learning has the potential to revolutionize many fields of medicine, helping to make faster and more correct decisions and improving current standards of treatment. Today, machines can analyze, learn, communicate, and understand processed data and are used in health care increasingly. This review explains different models and the general process of machine learning and training the algorithms. Furthermore, it summarizes the most useful machine learning applications and tools in different branches of medicine and health care (radiology, pathology, pharmacology, infectious diseases, personalized decision making, and many others). The review also addresses the futuristic prospects and threats of applying artificial intelligence as an advanced, automated medicine tool.

1 August 2017 in Stem Cell Research
Verified
Journal Article
Open access
MKMarta Klimczak
Marta Klimczak
PCPatrycja Czerwinska
Patrycja Czerwinska
SMSylwia Mazurek
Sylwia Mazurek
BSBarbara Sozańska
Barbara Sozańska
PBPrzemyslaw Biecek
Przemyslaw Biecek
MWMaciej Wiznerowicz
Maciej Wiznerowicz
Cellular reprogramming proceeds in a stepwise pathway initiated by binding and transcription of pluripotency factors followed by genome-wide epigenetic changes. Priming events, such as erasure of DNA methylation and chromatin remodeling determines the success of pluripotency acquisition later. Therefore, growing efforts are made to understand epigenetic regulatory network that makes reprogramming possible and efficient. Here, we analyze the role of transcriptional corepressor TRIM28, involved in heterochromatin formation, during the process of reprogramming of mouse somatic cells into induced pluripotent stem cells (iPS cells). We demonstrate that Trim28 knockdown (Trim28 KD) causes that emerging iPS cells differentiate immediately back into MEFs therefore they fail to yield stable iPS cell colonies. To better comprehend the mechanism of TRIM28 action in reprogramming, we performed a reverse-phase protein array (RPPA) using in excess of 300 different antibodies and compared the proteomic profiles of wild-type and Trim28 KD cells during reprogramming. We revealed the differences in the dynamics of reprogramming of wild-type and Trim28 KD cells. Interestingly, proteomic profile of Trim28 KD cells at the final stage of reprogramming resembled differentiated state rather than maintenance of pluripotency and self-renewal, strongly suggesting spontaneous differentiation of Trim28 KD cells back to their parental cell type. We also observed that action of TRIM28 in reprogramming is accompanied by differential enrichment of proteins involved in cell cycle, adhesion and stemness. Collectively, these results suggest that regulation of epigenetic modifications coordinated by TRIM28 plays a crucial role in reprogramming process.

1 March 2019 in Reports of Practical Oncology and Radiotherapy
Verified
Journal Article
Closed access
PCPatrycja Czerwinska
Patrycja Czerwinska
SMSylwia Mazurek
Sylwia Mazurek
IKIga Kołodziejczak
Iga Kołodziejczak
MWMaciej Wiznerowicz
Maciej Wiznerowicz
Induced pluripotent stem cells derived from normal somatic cells could be utilized to study tumorigenesis through overexpression of specific oncogenes, downregulation of tumor suppressors and dysregulation of other factors thought to promote tumorigenesis. Therefore, effective approaches that provide direct modifications of induced pluripotent stem cell genome are extremely needed. Emerging strategies are expected to provide the ability to more effectively introduce diverse genetic alterations, from as small as single-nucleotide modifications to whole gene amplification or deletion, all with a high degree of target specificity. To date, several techniques have been applied in stem cell studies to directly edit cell genome (ZFNs, TALENs or CRISPR/Cas9). In this review, we summarize specific gene delivery strategies that were applied to stem cell studies together with genome editing techniques, which enable a direct modification of endogenous DNA sequences in the context of cancer studies. (C) 2019 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.

1 May 2018 in Reports of Practical Oncology and Radiotherapy
Verified
Journal Article
Closed access
PCPatrycja Czerwinska
Patrycja Czerwinska
SMSylwia Mazurek
Sylwia Mazurek
MWMaciej Wiznerowicz
Maciej Wiznerowicz
As soon as induced pluripotent stem cells (iPSCs) reprogramming of somatic cells were developed, the discovery attracted the attention of scientists, offering new perspectives for personalized medicine and providing a powerful platform for drug testing. The technology was almost immediately applied to cancer studies. As presented in this review, direct reprogramming of cancer cells with enforced expression of pluripotency factors have several basic purposes, all of which aim to explain the complex nature of cancer development and progression, therapy-resistance and relapse, and ultimately lead to the development of novel anti-cancer therapies. Here, we briefly present recent advances in reprogramming methodologies as well as commonalities between cell reprogramming and carcinogenesis and discuss recent outcomes from the implementation of induced pluripotency into cancer research. (C) 2018 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.

29 July 2021 in Cells
Verified
Journal Article
Open access
PDF file
SMSylwia Mazurek
Sylwia Mazurek
UOUrszula Oleksiewicz
Urszula Oleksiewicz
PCPatrycja Czerwinska
Patrycja Czerwinska
JWJoanna Patrycja Wroblewska
Joanna Patrycja Wroblewska
MKMarta Klimczak
Marta Klimczak
MWMaciej Wiznerowicz
Maciej Wiznerowicz
TRIM28, a multi-domain protein, is crucial in the development of mouse embryos and the maintenance of embryonic stem cells’ (ESC) self-renewal potential. As the epigenetic factor modulating chromatin structure, TRIM28 regulates the expression of numerous genes and is associated with progression and poor prognosis in many types of cancer. Because of many similarities between highly dedifferentiated cancer cells and normal pluripotent stem cells, we applied human induced pluripotent stem cells (hiPSC) as a model for stemness studies. For the first time in hiPSC, we analyzed the function of individual TRIM28 domains. Here we demonstrate the essential role of a really interesting new gene (RING) domain and plant homeodomain (PHD) in regulating pluripotency maintenance and self-renewal capacity of hiPSC. Our data indicate that mutation within the RING or PHD domain leads to the loss of stem cell phenotypes and downregulation of the FGF signaling. Moreover, impairment of RING or PHD domain results in decreased proliferation and impedes embryoid body formation. In opposition to previous data indicating the impact of phosphorylation on TRIM28 function, our data suggest that TRIM28 phosphorylation does not significantly affect the pluripotency and self-renewal maintenance of hiPSC. Of note, iPSC with disrupted RING and PHD functions display downregulation of genes associated with tumor metastasis, which are considered important targets in cancer treatment. Our data suggest the potential use of RING and PHD domains of TRIM28 as targets in cancer therapy.